VECTOR B2B
Desconocido
LiverTarget: Next generation advanced RNA inhibition therapy to treat cardiometabolic disease
VECTOR B2B DRUG DEVELOPING ASSOCIACAO PARA INVESTIGACAO EM BIOTECNOLOGIA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-TOOL-06
RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that...
2022-05-24 - 2027-04-30 | Financiado
2022-05-24 - 2027-04-30 | Financiado
CoroPrevention: Personalized Prevention for Coronary Heart Disease
VECTOR B2B DRUG DEVELOPING ASSOCIACAO PARA INVESTIGACAO EM BIOTECNOLOGIA
participó en un
H2020:
H2020-SC1-BHC-2018-2020
European Coronary Heart Disease (CHD) burden is unsustainable. Better risk stratification tools and personalized care of patients are needed...
2019-12-13 - 2026-12-31 | Financiado
2019-12-13 - 2026-12-31 | Financiado
* No se disponen de datos de la empresa actual.